BioSpace News Archive

The Board of Directors of Oncopeptides AB has resolved, by virtue of the authorization by the Annual General Meeting held on June 28, 2022, to issue and immediately thereafter re-purchase a total of 3,940,607 class C shares.

Median Technologies (Euronext Growth - ALMDT) (Paris:ALMDT), whose Board of Directors approved on October 18, 2022 the consolidated IFRS financial statements for the first half of 2022 after a limited review, announces today its half-year results as well as revenues for the third quarter of 2022.

A Canadian startup that has created a digital assessment tool for monitoring Parkinson’s disease symptoms has won the 2022 AGE-WELL National Impact Challenge.

To address the growing need for simplified, rapid testing for Monkeypox, BioGX, a global provider of easy molecular diagnostic solutions, announced availability of Xfree PCR reagents for Sample-to-Answer Direct Sample PCR on multiple real-time PCR platforms including BioGX’s rapid “pixl” platform.

According to Nova one advisor, the global Cell-based Assays market size is expected to hit around USD 34.8 billion by 2030 from valued at USD 15.95 billion in 2021 and growing at a CAGR of 8.75% from 2022 to 2030

Beyond Air, Inc. and, through its affiliate Beyond Cancer, Ltd. announced that it will report financial results for its second fiscal quarter ended September 30, 2022 on Tuesday, November 8, 2022.

Inhibrx, Inc., a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced it will be presenting at multiple upcoming scientific conferences.

NyxoahSA announced that the Company will participate in the Jefferies London Healthcare Conference, which takes place November 15-17, 2022, at The Waldorf Hilton in London.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that abstracts highlighting clinical data for omaveloxolone and disease education data on Friedreich’s ataxia will be presented at the International Congress for Ataxia Research 2022 (“ICAR”) being held in Dallas, TX from November 1 – 4, 2022.

Castle Biosciences, Inc. (Nasdaq: CSTL) today announced new data from its prospective, multicenter DECIDE1 study in which DecisionDx®-Melanoma test results influenced 85% of clinicians’ decisions regarding the sentinel lymph node biopsy (SLNB) surgical procedure, demonstrating the role of the test’s results in guiding risk-aligned patient management decisions.